Companies
Acquired by KnowBe4
Acquired by Apple
Acquired by Capital D
Acquired by Oracle
Acquired by Siemens
Acquired by ERT Inc
IPO: AREC
IPO: ORTX
IPO: FRLN
IPO: ACHL
IPO: MGTX
Acquired by Facebook
IPO: BKNG
Explore our investments
-
Life Sciences investments
-
Investing since2016In collaboration with UCL Business
-
Total investment> $2bnOver $2bn of follow on funding for our companies
-
Public offerings4 IPOsFour Nasdaq IPOs since 2018
Featured investments
Universities should not be greedy with technology spin-offs | FT
Dave Grimm, Partner at AlbionVC, chats to John Gapper, Financial Times, on the opportunities that commercialising research presents, on the back of our very successful partnership with UCL.
UK universities take record low spinout stakes: ‘But that’s only half the battle’
David Grimm, Partner AlbionVC discusses university spinout terms and timelines with Sifted
Today, 90% of Russell Group universities have affiliated funds as reported by Sifted
Why We’re Bullish on London University Spinouts
Companies
-
Achilles TherapeuticsBiopharmaceutical company developing precision T cell therapies
Life SciencesIPO -
Apollo Therapeuticsbiopharmaceutical company advancing a robust pipeline of potentially transformative therapeutic programs Life SciencesGrowth
-
Axovia TherapeuticsGene therapy company developing disease-transformative medicines for ciliopathies Life SciencesEarly Stage
-
Bloomsbury GTXBiotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases Life SciencesExited
-
EpilepsyGTxBiotechnology company developing of cutting-edge gene therapies to treat focal refractory epilepsy Life SciencesEarly Stage
-
EpsilogenImmuno-oncology company targeting cancer with the IgE class of antibodies Life SciencesEarly Stage
-
Meira GTXVertically integrated, clinical stage gene therapy company Life SciencesIPO
-
NovalGenImmuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer Life SciencesEarly Stage
-
Orchard TherapeuticsBiotechnology company bringing transformative gene therapies to patients with serious and life-threatening orphan diseases Life SciencesIPO
-
Panangium TherapeuticsBiologic for retinal disease targeting a novel alternative pathway to VEGF Life SciencesEarly Stage
-
Quell TherapeuticsA clinical stage company transforming lives in immune mediated disease Life SciencesGrowth
-
Spur TherapeuticsBiopharmaceutical company focused on the development of liver-directed gene therapies Life SciencesIPO
